GLP-1 receptor agonists are one of the most revolutionary new classes of drugs in decades. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, sat down with Jens Juul Holst, MD, DMSc, and Lotte Bjerre Knudsen, DMSc, 2 pioneering scientists behind the discovery and development of GLP-1 RAs. Together, they traced the fascinating origin story of GLP-1 RAs and offered their thoughts on what comes next.<br><br>Related Content:<br>GLP-1s—From Gut Hormone Discovery to a Public Health Revolution

Should Everyone be on GLP-1s?

Healthy Dialogue

So the medicines are something that can help many people right now, but I don't think they should be the long-term solution. They should maybe be the long-term solution for some people. But if we don't fix the underlying problem where people can live a balanced and healthy life, but while that is not in place, you know, we do have these medicines that could actually help a lot of people.

GLP-1 receptor agonists, often just now called GLP-1s, are one of the most revolutionary new class of drugs that we have seen in decades. By now their benefits for weight management, controlling blood glucose and treating type 2 diabetes, and for improving cardiovascular health overall are widely known,

with significant benefits also for the kidney and for liver function, and indeed, every day we learn about new potential applications, from addiction treatment to dementia risk reduction, even improved cancer survivorship. So, what is the story behind these apparent miracle drugs?

And for obesity in particular, while it might be a bit dystopian to think of them as the cure for the entire obesity epidemic, they surely can play some major role, but what is that role exactly? I'm Derek Angus, a physician and senior editor at JAMA, and you're listening to Healthy Dialogue. Today, I have the pleasure of speaking with Jens Holst and Lottie Knudsen.

They played crucial roles in the discovery and development of GLP-1 receptor agonists. Both Jens and Lottie were guests at the recent JAMA Summit on Obesity, where thought leaders and experts from around the world came to the JAMA offices in Chicago to tackle the rapidly evolving landscape of obesity and metabolic disorders.

Should Everyone be on GLP-1s?

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Should Everyone be on GLP-1s?

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.